Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
Status:
Recruiting
Trial end date:
2022-07-07
Target enrollment:
Participant gender:
Summary
A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients
experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular
revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up
to a maximum of 60 mL/h), 1 mL/kg/h RNS60 (up to a maximum of 120 mL/h), or 1 mL/kg/h (up to
a maximum of 120 mL/h) placebo (normal saline) starting within 30 minutes of consent after
confirmation of candidacy for endovascular thrombectomy.